Crinetics Pharmaceuticals (CRNX) Long-Term Deferred Tax (2024)

Crinetics Pharmaceuticals (CRNX) recorded quarterly Long-Term Deferred Tax of $291.5 million in Q4 2024.

Crinetics Pharmaceuticals (CRNX) Long-Term Deferred Tax (2024) Analysis & Trends

Crinetics Pharmaceuticals' Long-Term Deferred Tax history runs 1 years deep, the most recent figure standing at $291.5 million for Q4 2024.

In Q4 2024, Long-Term Deferred Tax changed N/A year-over-year to $291.5 million; the TTM figure through Dec 2024 stood at $291.5 million (changed N/A YoY), while the FY2024 annual figure was $291.5 million, changed N/A from the prior year.
Long-Term Deferred Tax was $291.5 million for Q4 2024 at Crinetics Pharmaceuticals.
In the past five years, Long-Term Deferred Tax ranged from a high of $291.5 million in Q4 2024 to a low of $291.5 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Crinetics Pharmaceuticals	3.75 Bn	3.75 Bn	10.53 Mn

Download Data

Date	Value
Dec 31, 2024	291.54 Mn